Drug intelligence / Profile preview

XYF-13

Development stage: Unknown
Lead developer: Xi'an Yufan Biotechnology
Modality: Autologous CAR-T → CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
Administration: Intravenous

Overview

XYF-13 is an autologous CAR-T cell therapy under development for the treatment of recurrent glioblastoma. The therapy consists of T cells that are genetically modified to express a chimeric antigen receptor (CAR) targeting HPK1 (hematopoietic progenitor kinase 1). By inhibiting HPK1, which is involved in negative regulation of T-cell receptor signaling, XYF-13 aims to enhance anti-tumor immune responses. The drug is being developed by Xi'an Yufan Biotechnologies and has reached Phase 1 clinical trials in China for glioblastoma[1][2][4].

Targets

MAP4K1 (Hematopoietic progenitor kinase 1)

Beyond the preview

Go deeper on XYF-13.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on XYF-13.

Explore the full profile